Table 2.
Univariate Cox regression analysis for relapse of early-stage IBC patients with HR+.
| Factors | Univariate analysis | ||||
|---|---|---|---|---|---|
| HR | 95%CI | P | |||
| Lower | Upper | ||||
| Age (Years) | <37.5 vs ≥37.5 | 0.354 | 0.137 | 0.914 | 0.032 |
| Pathological type | NSIDC vs ILC vs NSIDC-CIS vs CIS-MI vs SGDC vs CC vs MC | 0.849 | 0.553 | 1.305 | 0.456 |
| Grade | 1 vs 2 vs 3 | 2.375 | 1.001 | 5.632 | 0.050 |
| Tumor diameter (cm) | <16 vs ≥16 | 4.216 | 0.978 | 18.177 | 0.054 |
| Menopausal status | No vs Yes | 1.022 | 0.401 | 2.601 | 0.964 |
| AJCC stage | I vs II | 2.092 | 0.881 | 4.964 | 0.094 |
| Sentinel lymph node | <7 vs ≥7 | 2.362 | 0.975 | 5.725 | 0.057 |
| Ki67 | <22.50% vs ≥22.50% | 4.684 | 1.989 | 11.033 | 0.000 |
| Chemotherapy | No vs Yes | 3.023 | 1.299 | 7.033 | 0.010 |
| Endocrine therapy | Anastrozole vs Aletrozole vs Tamoxifen vs Toremifen vs Exemestane | 1.010 | 0.487 | 2.096 | 0.979 |
| TYMS | <56.75% vs ≥56.75% | 2.507 | 1.049 | 5.991 | 0.039 |
| RRM1 | <68.80% vs ≥68.80% | 3.858 | 1.658 | 8.979 | 0.002 |
| TUBB3 | <39.60% vs ≥39.60% | 2.819 | 1.041 | 7.629 | 0.041 |
| TOP2A | <63.35% vs ≥63.35% | 6.021 | 2.342 | 15.480 | 0.000 |
| HER2 | <65.25% vs ≥65.25% | 0.200 | 0.080 | 0.501 | 0.001 |
| PTEN | <46.75% vs ≥46.75% | 0.270 | 0.109 | 0.666 | 0.004 |
IBC, invasive breast cancer; HR, hormonal receptor; HER2, human epidermal growth factor receptor 2; TYMS, thymidylate synthase; RRM1, ribonucleotide reductase M1; TUBB3, class III beta-tubulin; TOP2A, topoisomerase II alpha; PTEN, phosphatase and tensin homolog; NSIDC, non-specific invasive ductal carcinoma; ILC, invasive lobular carcinoma; NSIDC-CIS, non-specific invasive ductal carcinoma with carcinoma in situ; CIS-MI, carcinoma in situ with microinvasion; SGDC, sweat gland differentiated carcinoma; CC, cribriform carcinoma; MC, mucoid carcinoma; AJCC, American Joint Committee on Cancer; HR, hazard ratio; CI, confidence interval. The bolded values present P<0.05.